Apogee Therapeutics Provides Pipeline Progress and Reports

4 days ago · Apogee Therapeutics 2024 Virtual R&D Day to be held on December 2, 2024 at 10am ET: The company plans to highlight its progress across its pipeline and showcase its …

CouponFollow Extension

$50
OFF

Verve Therapeutics Announces Pipeline Progress And Reports

1 week from now

Nov 5, 2024 · Net Loss: Net loss was $50.1 million, or $0.59 basic and diluted net loss per share, for the third quarter of 2024, compared to $45.8 million, or $0.72 basic and diluted net loss per …

globenewswire.com

$27
OFF

Oruka Therapeutics Reports Third Quarter 2024 Financial

1 week from now

2 days ago · Net cash used in operating activities was $27.8 million for the third quarter of 2024. The Company expects this cash to provide runway through 2027. Research and Development …

biospace.com

FAQs about Apogee Therapeutics Provides Pipeline Progress and Reports Coupon?

When is apogee Therapeutics virtual R&D day 2024?

Apogee Therapeutics 2024 Virtual R&D Day to be held on December 2, 2024 at 10am ET: The company plans to highlight its progress across its pipeline and showcase its path to reshaping the standard of care in I&I by bringing forward monotherapy and combination treatments that offer the potential for best-in-class efficacy and improved dosing. ...

How much did apogee Therapeutics raise?

Apogee Therapeutics raised $420 million at $62/share, expanding their financial runw... SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment... ...

Who is apogee Therapeutics?

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications. ...

Does apogee Therapeutics apg777 have a long half-life?

SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for th... Apogee Therapeutics' APG777 shows promising Phase 1 results for AD, with a notably long half-life potentially reducing dosing frequency. ...

What is apogee's Phase 1 apg990 trial?

In August 2024, Apogee initiated its Phase 1 APG990 trial, designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers. The study will evaluate the safety, tolerability and PK of APG990 and is expected to enroll approximately 40 healthy adults across 5 cohorts. ...

Should you buy apogee Therapeutics stock?

Apogee Therapeutics stock has declined by 34% since a previous recommendation to buy, while the S&P 500 is up 7.7%. Apogee Therapeutics raised $420 million at $62/share, expanding their financial runw... ...